Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
Rhea-AI Summary
Xenetic Biosciences (NASDAQ:XBIO), a biopharmaceutical company focusing on innovative immune-oncology technologies for hard-to-treat cancers, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Jim Parslow, the company's Interim CEO and CFO, delivered a presentation at the event. The video webcast of this presentation is now available on the Events page in the Investors section of Xenetic's website (www.XeneticBio.com) and will remain accessible for 90 days.
Positive
- Participation in a major investment conference, potentially increasing visibility to investors
- Availability of presentation webcast on company website, enhancing transparency and investor communication
Negative
- None.
News Market Reaction – XBIO
In the trading session that priced this news, XBIO gained 1.93%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FRAMINGHAM, MA / ACCESSWIRE / September 11, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that Jim Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic, presented at the H.C. Wainwright 26 th Annual Global Investment Conference.
The video webcast of the presentation is now accessible on the Events page in the Investors section of the Company's website (www.XeneticBio.com) and will be archived for 90 days.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
CONTACT:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View the original press release on accesswire.com